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Infections caused by opportunistic fungal pathogens have reached concerning numbers
due to the increase of the immunocrompromised human population and to the
development of antifungal resistance. This resistance is often attributed to the action of
multidrug efflux pumps, belonging to the ATP-binding cassette (ABC) superfamily and the
major facilitator superfamily (MFS). Although many studies have focused on the role of
ABC multidrug efflux transporters, little is still known on the part played by the Drug:H+
Antiporter (DHA) family of the MFS in this context. This review summarizes current
knowledge on the role in antifungal drug resistance, mode of action and phylogenetic
relations of DHA transporters, from the model yeast S. cerevisiae to pathogenic yeasts
and filamentous fungi. Through the compilation of the predicted DHA transporters in the
medically relevant Candida albicans, C. glabrata, C. parapsilosis, C. lusitaniae, C. tropicalis,
C. guilliermondii, Cryptococcus neoformans, and Aspergillus fumigatus species, the fact
that only 5% of the DHA transporters from these organisms have been characterized
so far is evidenced. The role of these transporters in antifungal drug resistance and in
pathogen-host interaction is described and their clinical relevance discussed. Given the
knowledge gathered for these few DHA transporters, the need to carry out a systematic
characterization of the DHA multidrug efflux pumps in fungal pathogens, with emphasis
on their clinical relevance, is highlighted.
Keywords: multidrug resistance efflux pumps, drug:H+ antiporters, antifungal drug resistance, pathogenic fungi,
Candida species
INTRODUCTION
The multidrug resistance (MDR) phenomenon, characterized
by the simultaneous acquisition of resistance to chemically
and structurally different compounds (Sá-Correia et al., 2009;
Morschhauser, 2010), poses a severe problem in the treatment
of fungal infections. This is particularly relevant since the num-
ber of infections caused by opportunistic fungal pathogens has
increased considerably in recent years due to the widespread
use of antifungal drugs in immunocompromised patients, such
as individuals undergoing chemotherapy, HIV-infected, or AIDS
patients (Morschhauser, 2010).
There are mainly four mechanisms by which a cell can deal
with a toxic compound: (i) drug target alteration, (ii) drug inac-
tivation, (iii) reduced uptake, or (iv) active extrusion (Ernst et al.,
2010). The latter occurs mainly due to the action of membrane
transporters which belong to one of two superfamilies in fungi:
the ATP-binding cassette superfamily (ABC) and the major facil-
itator superfamily (MFS) (Cannon et al., 2009; Sá-Correia et al.,
2009; Morschhauser, 2010). The role of the ABCmultidrug trans-
porters in antifungal resistance in clinical isolates has been well
characterized in the past decades. However, much less attention
has been drawn to the expected role of the Drug:H+ Antiporter
(DHA) family of the MFS.
In this paper, knowledge gathered so far on the role of the DHA
family in antifungal drug resistance is reviewed, with emphasis on
its clinical relevance. Although starting from what was found, in
this context, in the model yeast Saccharomyces cerevisiae, particu-
lar focus is given to the DHA transporters found to occur, based
on phylogenetic analysis, in pathogenic yeasts of the Candida
genus and also in Cryptococcus neoformans, and Aspergillus fumi-
gatus. Current challenges and expected impact of research in this
topic is finally discussed.
THE DRUG:H+ ANTIPORTER FAMILY: LESSONS FROM
SACCHAROMYCES CEREVISIAE
Upon the release of the complete Saccharomyces cerevisiae genome
sequence (Goffeau et al., 1996), a total of 22 transporters belong-
ing to the MFS were identified and clustered into two families: the
drug:H+ antiporter family 1 (DHA1) and 2 (DHA2). These fami-
lies differ mainly in the number of transmembrane spans (TMS),
with the first having 12 and the second 14 TMS (Sá-Correia et al.,
2009).
S. cerevisiae has 12 DHA1 and 10 DHA2 transporters, most
of which have been implicated in MDR, while some are yet to
be characterized (reviewed in Sá-Correia et al., 2009). Most of
these transporters were found to confer resistance to a large num-
ber of unrelated chemicals. Given this apparent promiscuity, their
exact mode of action as multidrug resistance determinants is con-
troversial. For most S. cerevisiae DHA transporters a role in the
physiology of the cell was further identified. That is the case
of ScTpo1-4 and ScQdr3, which confer resistance to toxic lev-
els of polyamines (Tomitori et al., 2001; Albertsen et al., 2003;
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Teixeira et al., 2011), of ScDtr1, that facilitates the translocation
of bisformyl dityrosine through the prospore membrane during
spore wall maturation (Felder et al., 2002), of ScQdr2, involved in
potassium homeostasis (Vargas et al., 2007), and of ScAqr1, that
has been proposed to excrete amino acids, such as homoserine
and threonine (Velasco et al., 2004).
Most of the characterized transporters of S. cerevisiae, both
from DHA1 and DHA2 subfamilies, confer resistance to more
than one different growth inhibitory compound, with ScTpo1
being, by far, the one with the broadest range of predicted sub-
strates (Sá-Correia et al., 2009). Among these compounds, some
are of particular relevance in the combat against fungal phy-
topathogens. For example, ScFlr1 was found to confer resistance
against the agricultural fungicides benomyl (Brôco et al., 1999)
and mancozeb (Teixeira et al., 2008, 2010). The most interesting
finding, however, is that, even though this is a non-pathogenic
species, a lot of these efflux pumps confer resistance to or are up-
regulated by widely used clinically relevant antifungal drugs, such
as fluconazole (ScFlr1, ScQdr1, ScYhk8, and ScAzr1) (Tenreiro
et al., 2000; Nunes et al., 2001; Barker et al., 2003), ketoconazole
(ScAqr1, ScQdr1, ScQdr2, ScAzr1) (Tenreiro et al., 2000, 2002;
Nunes et al., 2001), itraconazole (ScYhk8) (Barker et al., 2003)
and caspofungin (ScTpo1) (Markovich et al., 2004). Some of
them even confer resistance to more than one of these antifungal
agents, as is the case of ScAzr1 and ScQdr1.
The paradigmatic case of the study of DHA transporters in S.
cerevisiae highlights three important facts: (1) the existence and,
thus, function of 20 out of 22 of these transporters remained
concealed until the genome sequence was disclosed; (2) these
transporters were indeed found to confer multidrug resistance,
but also to play important roles in S. cerevisiae physiology; and (3)
there is significant functional overlap between these transporters,
making the discovery of their function a bigger challenge. The
functional analysis of the S. cerevisiae DHA transporters provides
clues on the function of homolog transporters from pathogenic
yeast and filamentous fungi, but also suggests that their role tends
to be elusive.
DRUG:H+ ANTIPORTER FAMILY: DISSEMINATION IN
PATHOGENIC YEAST AND FUNGI
The Candida DHA1 and DHA2 transporters considered in this
review are those predicted to be encoded in the genomes of C.
albicans, C. tropicalis, C. parapsilosis, C. guilliermondii, C. lusi-
taniae, and C. glabrata (Dias et al., 2010; Dias and Sá-Correia,
2013, in press). The DHA1 and DHA2 proteins encoded in the
genomes of A. fumigatus and C. neoformans were identified using
the annotation provided by the Aspergillus Genome Database
(AspGD—http://www.aspgd.org/) and, based on the BlastP algo-
rithm, using the S. cerevisiae DHA1 and DHA2 proteins to query
the Genbank database, respectively. A total of 185 full-size DHA1
proteins and 85 full-size DHA2 proteins were found to be encoded
in these eight fungal species, and clustered according to the
phylogenetic trees displayed in Figure 1.
This review considers DHA1 proteins belonging to 20 previ-
ously reported phylogenetic clusters, labeled A to V (Dias et al.,
2010; Dias and Sá-Correia, in press), and describes the occurrence
of 8 new clusters, which include only A. fumigatus genes (clusters
1–4 and 6–7) or A. fumigatus and C. neoformans genes (clus-
ter 5) (Figure 1). It becomes clear that the A. fumigatus genome
encodes a higher number and higher diversity of DHA1 proteins
compared with hemiascomycetous genomes. However, A. fumi-
gatus lacks homologs to the S. cerevisiae Dtr1, Hol1, Tpo4 and
Flr1 transporters (Figure 1). The genome of the basidiomycete
yeast C. neoformans comprises a total of 9 DHA1 proteins, includ-
ing homologs of S. cerevisiae Qdr1/Qdr2/Aqr1, Tpo2/Tpo3 and
Flr1 proteins, one homolog of the C. albicans Tmp1/Tmp2 pro-
teins and three proteins residing in the new phylogenetic cluster 5
(Figure 1).
The DHA2 proteins considered or identified in this study
are distributed throughout 8 previously reported phylogenetic
clusters (Dias and Sá-Correia, 2013), plus 11 newly defined
clusters, composed only by A. fumigatus and/or C. neoformans
proteins (labeled 1–11). The A. fumigatus genome encodes a
total of 33 DHA2 transporters, two thirds of which reside in
clusters lacking hemiascomycetous DHA2 members. A. fumiga-
tus genome does not include homologs of Sge1/Azr1/Vba3/Vba5
or Atr1/YMR279C proteins. A total of 7 DHA2 proteins were
found in the C. neoformans genome, among which only one
S. cerevisiae homolog is found, clustering with Vba1/Vba2
(Figure 1).
Altogether, the abundance of predicted DHA transporters in
the Candida, Cryptococcus and Aspergillus species considered,
reaching 87 for A. fumigatus, is very high, strongly suggesting
that these transporters must play an important function in these
organisms. Among almost 300 ORFs compiled in Figure 1 only
12 have already been characterized, corresponding to around 5%
of the total number. Their predicted involvement in drug resis-
tance highlights the importance of characterizing all of them in a
systematic way.
ROLE OF DHA TRANSPORTERS IN ANTIFUNGAL DRUG
RESISTANCE
Only a few DHA transporters have been linked to antifungal
drug resistance in pathogenic fungi (Table 1). This appears to
be mostly due to lack of characterization efforts. The C. albi-
cans drug efflux pump Mdr1 was the first protein identified as
a multidrug MFS transporter in a pathogenic fungus. CaMdr1
expression was found to confer resistance to fluconazole and
ketoconazole, but not to itraconazole or miconazole, in S. cere-
visiae, while overexpression in C. albicans leads to fluconazole
resistance (Goldway et al., 1995; Hiller et al., 2006). CaNag3 and
CaNag4 have also been shown to confer resistance to several anti-
fungal drugs, such as cycloheximide, 4-nitroquinoline-N-oxide
and 1–10 phenanthroline, being thus proposed to be multidrug
efflux pumps (Yamada-Okabe and Yamada-Okabe, 2002). The C.
albicansDHA1 transporter CaFlu1 was found to complement flu-
conazole hypersusceptibility in a S. cerevisiae pdr5 mutant, but
not to have a significant role in fluconazole resistance in C. albi-
cans (Calabrese et al., 2000). On the other hand, Flu1 was more
recently shown to confer resistance to the salivary human antimi-
crobial peptide histatin 5, playing a direct role in its efflux from C.
albicans cells, thus reducing histatin 5 toxicity (Li et al., 2013). Of
a total of 26 DHA transporters found to be encoded by C. albicans
genome, 18 are still uncharacterized.
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FIGURE 1 | Continued
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FIGURE 1 | Phylogenetic analysis of DHA1 and DHA2 transporters
gathered from the S. cerevisiae S288C reference strain and from eight
clinically important fungal species - C. albicans, C. tropicalis, C.
parapsilosis, C. guilliermondii, C. lusitaniae, C. glabrata, A. fumigatus
and C. neoformans - using the PROTDIST/NEIGHBOR packages of
PHYLIP suite, as detailed in (Dias and Sá-Correia, 2013, in press). (A)
Radial phylogram showing the amino acid sequence similarity distances
between these 197 full-size DHA1 transporters. (B) Circular cladogram
showing the corresponding tree topology. The DHA1 proteins are distributed
into 20 known phylogenetic clusters, labeled using letters and based on
previous cluster annotation (Dias and Sá-Correia, in press), and 8 new
(Continued)
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FIGURE 1 | Continued
phylogenetic clusters (clusters 1–4 and 6–7) comprising only members of
the filamentous fungi. (C) Radial phylogram showing the amino acid
sequence similarity distances between these 95 full-size DHA2
transporters. (D) Circular cladogram showing the corresponding tree
topology. The DHA2 proteins are distributed into 8 known phylogenetic
clusters, labeled using letters and based on a previous cluster annotation
(Dias and Sá-Correia, 2013), and 11 new phylogenetic clusters (clusters
1–11) comprising only members of the filamentous fungi. The DHA1 and
the DHA2 proteins encoded in the genome of S. cerevisiae S288c strain
and biochemically characterized MgMfs1 and BcMfs1 DHA2 fungal
proteins were used as functional reference and the corresponding names
are indicated in the phylogenetic trees. The ARN and GEX proteins (Dias
and Sá-Correia, 2013), were not included in this analysis.
Close homologs to CaMdr1 were found in both C. dubliniensis
and C. tropicalis. In the first, inactivation of the gene was shown
to result in an increased susceptibility to fluconazole (Wirsching
et al., 2001), while in the latter its expression increased when
cells were treated with increasing concentrations of fluconazole
and, at the same time, developed cross-resistance to azoles and
terbinafine (Barchiesi et al., 2000).
C. glabrata, a pathogenic yeast that is phylogenetically closer
to S. cerevisiae than to other Candida species, shows a high level
of intrinsic resistance to fluconazole. However, the DHA trans-
porter CgFlr1, a CaMdr1 homolog, was found to confer resistance
to benomyl, in a strain that was already a mutant for both CDR1
and CDR2 genes, but not to fluconazole or other azoles (Chen
et al., 2007). More recently, three additional DHA1 transporters
were characterized in what concerns their contribution to the
MDR phenomenon and their role in antifungal drug resistance.
CgQdr2, CgAqr1, and CgTpo3 were found to be involved in mul-
tidrug resistance as they confer resistance to a wide variety of
toxic compounds (Costa et al., 2013a,b, 2014), the most relevant
being, for CgQdr2, the imidazoles clotrimazole, miconazole, tio-
conazole, and ketoconazole (Costa et al., 2013b), for CgAqr1, the
antifungal drugs flucytosine and, less significantly, clotrimazole
(Costa et al., 2013a) and for CgTpo3 the azole antifungals clotri-
mazole, ketoconazole, miconazole, tioconazole, itraconazole, and
fluconazole (Costa et al., 2014). The role of CgAqr1 and CgTpo3
transporters in acetic acid (Costa et al., 2013a) and polyamine
(Costa et al., 2014) resistance, respectively, is also an interesting
feature given that Candida species have often to thrive in acetic
acid and polyamine rich environments such as the vaginal mucosa
or the urogenital tract, respectively.
For Aspergillus fumigatus, the transporter Mfs56 from the
DHA2 family has been characterized and found to have a role
in the resistance to itraconazole, posaconazole and ravuconazole
(Bowyer et al., 2012). Also, the AfMdr3 transporter has been
found to be overexpressed in cells treated with amphotericin B
(Gautam et al., 2008). Interestingly, two characterized multidrug
transporters from the phytopathogenic fungi Botrytis cinerea,
Bcmfs1 (Hayashi et al., 2002), and Mycosphaerella graminicola,
Mgmfs1 (Roohparvar et al., 2007), are shown to cluster together
with cluster 10 (Figure 1). Mgmfs1 in particular was found to
confer resistance to azoles and cycloheximide, among many other
tested compounds (Roohparvar et al., 2007), suggesting that a
similar function may be performed by the remaining members
of the DHA2 cluster 10.
DRUG:H+ ANTIPORTER CLINICAL IMPACT: WHAT’S KNOWN
ANDWHAT IS THERE TO BE FOUND
The clinical impact of the DHA transporters in fungal pathogens
is yet to be fully investigated. So far, only a couple of them have
been shown to effectively contribute to the development, pro-
gression, or persistence of the infection in the host (Table 1).
That is the case of C. albicans Mdr1, which has been found to be
consistently expressed in high values in fluconazole resistant clin-
ical isolates (Wirsching et al., 2000a,b), the same being observed
for C. dubliniensis Mdr1 (Wirsching et al., 2001). CaNag3 and
CaNag4 have also been shown to be involved in C. albicans vir-
ulence, as adult mice infected intravenously with 106 or 107 cells
of the canag3, canag4 or canag3canag4 mutants lived for at
least 4 weeks (in the lowest cell concentration for single mutants,
and both concentrations for double mutant), compared with a
maximum of 11 days for the lowest concentration of the wild
type (Yamada-Okabe and Yamada-Okabe, 2002). Very recently,
the deletion of C. albicans Qdr1, Qdr2, and Qdr3 transporters
was found to lead to defects in biofilm architecture and thick-
ness and to attenuate virulence in a mouse model (Shah et al.,
2014). Although the exact mechanism underlying this observa-
tion was not clarified, the expression of these transporters was
found to have a deep effect in membrane lipid composition,
which may underly the observed phenotypes (Shah et al., 2014).
The C. glabrata DHA transporters CgAqr1 and CgTpo3 were also
suggested to contribute to the survival of this pathogen within the
host, as they confer resistance to acetic acid (Costa et al., 2013a)
and polyamines (Costa et al., 2014), respectively, which accu-
mulate to inhibitory concentrations in Candida infection prone
environments. Indeed, the concentration of lactic or acetic acid
can reach up to 125mM in the vaginal tract, particularly under
bacterial vaginosis (Chaudry et al., 2004), whereas polyamine
concentrations can reach up to 15mM spermine, 5mM spermi-
dine, and 3mM putrescine in the urogenital tract (Tyms, 1989).
Of the high number of MFS transporters that fungal genomes
encode, only a reduced amount has been shown to be involved
in MDR or to be able to confer resistance to antifungal drugs,
and an even lower number has been described as clinically rel-
evant, so far. The lack of information on the clinical impact
of fungal DHA transporters may be associated with the types
of experiments carried out in this context. For instance, in
C. albicans, the upregulation of the ABC transporters CaCDR1
and CaCDR2 in fluconazole-resistant isolates, which has used to
assess their clinical relevance, was assessed mostly by targeted
gene expression analysis (Sanglard et al., 1995, 1997), or in a
few cases by the genome-wide analysis of the transcriptional
response to antifungal drugs (Karababa et al., 2004; Liu et al.,
2007). Furthermore, the impact of these transporters may not
depend merely on their over-expression. For example, polymor-
phic mutant alleles of CaMDR1 have been found among clinical
isolates, inducing distinct drug resistance profiles (Gupta et al.,
1998). More detailed analysis of the expression and sequence
variation of DHA encoding genes in clinical isolates is likely to
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Table 1 | DHA1 and DHA2 transporters predicted from the genome sequences of Candida spp., Aspergillus fumigatus, and Cryptococcus
neoformans.
Species Total # Characterized # Characterized ORFs Description and role in Drug/Stress resistance or virulence
Drug:H+ Antiporter 1 (DHA1) family members
C. albicans 18 7 orf19.5604/MDR1 Methotrexate is preferred substrate; overexpression in drug-resistant
clinical isolates confers fluconazole resistance; repressed in young
biofilms
orf19.6577/FLU1 Involved in histatin 5 efflux
orf19.2158/NAG3 Required for wild-type mouse virulence and cycloheximide resistance;
Spider biofilm repressed
orf19.2160/NAG4 Required for wild-type mouse virulence and wild-type cycloheximide
resistance
orf19.508/QDR1 Involved in biofilm architecture and thickness and virulence
orf19.6992/QDR2 Involved in biofilm architecture and thickness and virulence
orf19.136/QDR3 Involved in biofilm architecture and thickness and virulence
C. glabrata 10 4 CAGL0J09944g/AQR1 Involved in resistance to flucytosine, imidazoles, and acetic acid
CAGL0H06017g/FLR1 Confers resistance to benomyl; gene is downregulated in azole-resistant
strain
CAGL0I10384g/TPO3 Confers imidazole and triazole drug resistance; involved in polyamine
homeostasis; activated by CgPdr1
CAGL0G08624g/QDR2 Confers imidazole drug resistance, involved in clotrimazole efflux;
activated by CgPdr1p; upregulated in azole-resistant strain
C. parapsilosis 28 0
C. lusitaniae 17 0
C. tropicalis 18 0
C. guilliermondii 31 0
C. neoformans 9 1 CNA07070 Dityrosine transporter
A. fumigatus 54 0
Drug:H+ Antiporter 2 (DHA2) family members
C. albicans 8 1 orf19.2350 Affects filamentous growth
C. glabrata 5 0
C. parapsilosis 6 0
C. lusitaniae 7 0
C. tropicalis 8 0
C. guilliermondii 11 0
C. neoformans 7 2 CNC03290 Tetracycline efflux protein
CND00440/aflT Aflatoxin efflux pump
A. fumigatus 33 2 Afu6g09710/gliA Predicted glioxin transporter
Afu1g05010/mfs56 Mutation causes increased azole sensitivity
The total predicted number and the number of characterized DHA transporters are accounted for. The description and role in drug/stress resistance or virulence of
the few characterized DHA is highlighted (adapted from CGD and AspGD).
provide clues on their impact in the acquisition ofMDR in clinical
settings.
CONCLUSIONS AND PERSPECTIVES
Given their predicted role in antifungal drug resistance, a few
DHA transporters in pathogenic yeasts and fungi have already
been characterized. So far, their characterization suggested inter-
esting roles in antifungal drug resistance and, in some cases, in
host-pathogen interactions. However, only 5% of the predicted
DHA transporters in the 8 fungal pathogens considered in this
review have ever been studied. It appears, thus, crucial to study
this underappreciated family of transporters, as they may provide
decisive insights into the mechanisms underlying antifungal drug
resistance that may guide more efficient fungal infection diagno-
sis, prophylaxis, and therapeutics. Furthermore, unlike what has
been observed for ABC drug efflux pumps, which are widespread
from bacteria to man, the DHA family appears to be strictly
conserved within bacteria and fungi, turning these proteins into
interesting candidates as targets for the development of new
antifungal drugs.
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